Drugs / Palifosfamide

Trials 6 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00421135 Feb 2006 → Oct 2007 cancer of unknown primary site Alaunos Therapeutics Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00439686 Feb 2006 → Jun 2008 sarcoma Alaunos Therapeutics Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01703754 Apr 2013 → Aug 2014 breast carcinoma Alaunos Therapeutics Terminated No outcome recorded
Phase 2 NCT01808534 Feb 2013 → Nov 2014 adult central nervous system germ cell tumor, adult teratoma, extragonadal nonseminomatous germ cell tumor, extragonadal seminoma +2 Indiana University Terminated No outcome recorded
Phase 2 NCT00718484 Aug 2008 → Apr 2012 soft tissue sarcoma Alaunos Therapeutics Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT01168791 Jul 2010 → Mar 2013 soft tissue sarcoma Alaunos Therapeutics Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Palifosfamide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00718484
3

NCT01168791

NCT01703754

NCT01808534

Known as IPM “A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer” NCT00421135
Known as Isophosphoramide Mustard “A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer” NCT00421135
Known as Isophosporamide Mustard “A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma” NCT00439686
Known as ZIO-201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00439686
1

NCT00421135

Modality Small molecule Small molecule chemotherapy, IV administration” NCT01703754
Route Intravenous Intravenous Isophosphoramide Mustard (IPM)” NCT00421135